DAVID M NANUS, MD
Osteopathic Medicine at 70 St, New York, NY
License number
New York 154617
Category
Osteopathic Medicine
Type
Internal Medicine
License number
New York 154617
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
520 E 70Th St, New York, NY 10021
Phone
(646) 962-2072
(646) 962-1603 (Fax)
(646) 962-1603 (Fax)
Personal information
See more information about DAVID M NANUS at radaris.comName
Address
Phone
139 Kingsbury Rd, New Rochelle, NY 10804
2 N Cairngorm Rd, New City, NY 10956
New York, NY
139 Kingsbury Rd, New Rochelle, NY 10804
393 W End Ave #10D, New York, NY 10024
Professional information
Executive Vice President At Ls Power Equity Advisors
Position:
Executive Vice President at LS Power Equity Advisors
Location:
New York, New York
Industry:
Venture Capital & Private Equity
Work:
LS Power Equity Advisors
since Mar 2005
-
Executive Vice President
Lazard
Mar 2003 - Mar 2005
-
Vice President
Dresdner Kleinwort Wasserstein
Jul 2001 - Mar 2003
-
Associate
ITU Ventures
2000 - 2001
-
Campus Partner
Arthur Andersen
Sep 1996 - May 2000
-
Senior Associate
Education:
Columbia University - Columbia Business School 1999 - 2001
MBA, Finance Cornell University 1992 - 1996
BS, Applied Economics and Business Management
MBA, Finance Cornell University 1992 - 1996
BS, Applied Economics and Business Management
Dr. David M Nanus, New York NY - MD (Doctor of Medicine)
Specialties:
Oncology, Medical Oncology
Address:
525 E 68Th St SUITE 900, New York 10065
(646) 962-2072 (Phone), (212) 746-6645 (Fax)
(646) 962-2072 (Phone), (212) 746-6645 (Fax)
Certifications:
Internal Medicine, 1985, Medical Oncology, 1987
Awards:
Healthgrades Honor Roll
Languages:
English, Spanish
Hospitals:
525 E 68Th St SUITE 900, New York 10065
NewYork-Presbyterian/Weill Cornell Medical Center
525 East 68Th St, New York 10065
NewYork-Presbyterian/Weill Cornell Medical Center
525 East 68Th St, New York 10065
Education:
Medical School
Rosalind Franklin University of Medicine and Science / Chicago Medical School
Graduated: 1982
U Wisc Hosp Clins
Bronx Muni Hosp Ctr
Meml Sloan Kettering Ctr
Rosalind Franklin University of Medicine and Science / Chicago Medical School
Graduated: 1982
U Wisc Hosp Clins
Bronx Muni Hosp Ctr
Meml Sloan Kettering Ctr
David M Nanus, New York NY
Specialties:
Oncologist
Address:
525 E 68Th St, New York, NY 10065
520 E 70Th St, New York, NY 10021
520 E 70Th St, New York, NY 10021
Education:
Rosalind Franklin University, Chicago Medical School - Doctor of Medicine
Memorial Sloan-Kettering Cancer Center - Fellowship - Oncology (Internal Medicine)
Jacobi Medical Center - Residency - Internal Medicine
Memorial Sloan-Kettering Cancer Center - Fellowship - Oncology (Internal Medicine)
Jacobi Medical Center - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Oncology (Internal Medicine)
David Michael Nanus, New York NY
Specialties:
Internal Medicine, Medical Oncology, Hematology & Oncology, Hematology
Work:
NewYork-Presbyterian / Weill Cornell
525 E 68Th St, New York, NY 10065 Cornell Hematology/Oncology Faculty Practice Group
520 E 70Th St, New York, NY 10021
525 E 68Th St, New York, NY 10065 Cornell Hematology/Oncology Faculty Practice Group
520 E 70Th St, New York, NY 10021
Education:
Rosalind Franklin University (1982)
Combined Interferon Alfa And Lipsosmal-Encapsulated All-Trans Retinoic Acid, Including Preparation And Use
US Patent:
2002000, Jan 3, 2002
Filed:
Mar 16, 2001
Appl. No.:
09/811346
Inventors:
David Nanus - New York NY, US
Assignee:
Aronex Pharmaceuticals, Inc.
International Classification:
A61K009/127, A61K038/21, A61K031/203
US Classification:
424/450000, 424/085700, 514/559000
Abstract:
Alfa interferon (-IFN or alpha-interferon) and liposomal all-trans retinoic acid is useful in cancer treatment with particular reference to renal cancer. Optionally, a regimen of -interferon from about 3 to about 5 million units sc daily and liposomal all-trans retinoic acid at from about 15 mg/mto about 90 mg/m, or about 140 mg/m, or about 300 mg/mor more. Dosage periodicity of about three times per week for both drugs in about 8 week cycles is useful.